|
Published by: Datamonitor
Published: Aug. 23, 2001 - 75 Pages
Table of Contents
DATAMONITOR HEALTHCARE
CONTACT DETAILS
EXECUTIVE SUMMARY
Scope
Datamonitor insight into the GAD market
Key metrics
TABLE OF CONTENTS
EPIDEMIOLOGY
GAD overview
Definition
Comorbidities
Patient potential
Prevalence
Gender differences
Epidemiological conclusion
CLINICAL PRACTICE
Introduction
Diagnosis
Guidelines in existence
Physician diagnosis rate
Treatment
Breakdown of GAD in anxiety disorders
First line GAD treatment
Overall treatment of GAD
Influence on GAD marketing
Venlafaxine is the dominant treatment for GAD
The strength of efficacy clinical data
The high level of comorbidity and relapse rate
CURRENT GAD MARKET
Antidepressant use in GAD
Effexor XR
Paxil
Remeron
Serzone
Prozac
Zoloft
Luvox
Other antidepressants
Anxiolytic use in GAD
Benzodiazepines
Buspar
Other marketed drugs used in GAD
Atarax
Antipsychotics
The global GAD market 2001
THE FUTURE DECODED
Unmet needs in treating GAD
The GAD R&D pipeline
Efexor
Paroxetine
Sertraline
Pagoclone
NGD 91-3
Pregabalin
Lesopitron
The GAD market 2001-2008
Factors influencing the future GAD market
Future drug launches
GAD market forecast to 2008
GAD market forecast 2005
GAD market forecast 2008
APPENDIX
Datamonitor's Central Nervous System Business Unit
Table of tables
Epidemiology
Clinical trials
Websites
R&D research methodology
Introduction
Hypothesis formulation
Hypothesis testing
Data verification and quality control
Physician research questionnaire
Diagnosis
Treatment
Unmet needs
Pricing data
Introduction
Source prices
Ex-manufacturer, wholesaler and retail prices
Data validation and margin calculation
Quality control
Patent expiries
AbstractDatamonitor's Strategic Perspectives 2001: Anxiety Disorders series of eight reports form a comprehensive review of major anxiety and eating disorder markets. Each report utilizes primary research data in the seven leading healthcare markets and investigates the current state of affairs in each market. Furthermore they provide an in-depth analysis of the current pipeline, estimated drug launches and the future direction of each anxiety disorder. Anxiety Disorders covered: Eating Disorders (Anorexia Nervosa and Bulimia Nervosa) Generalized Anxiety DisorderObsessive Compulsive Disorder Panic DisorderPhobias (Specific Phobia and Agoraphobia)Post Traumatic Stress DisorderPremenstrual Dysphoric Disorder Social Anxiety Disorder
Get Full Details About This Report >>
|
